Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines

Abstract

Six permanent human tumor cell lines (OV-MZ-1 to 6) were established from 6 patients with serous adenocarcinomas of the ovary. These cell lines were derived from both solid tumors and ascites, from pre-treated and untreated patients, and are available over a range of in vitro passage numbers. The tumor cells grow as monolayers and develop foci of "piled-up' cells in confluent cultures. Flow cytophotometry showed that all the lines exhibited DNA hyperdiploidy with DNA tetraploidy in one cell line and DNA aneuploidy in the other cell lines. The mean population doubling time ranged from 24 to 52 hr. Transmission electron microscopy demonstrated that the tumor cells of all cell lines exhibited features of epithelial differentiation such as desmosomes and intracellular gland-like lumina. Immunocytochemical analysis showed that the co-expression of cytokeratins and vimentin, which is a feature of ovarian serous cystadenocarcinomas in situ, was fully preserved in the majority of cell lines. The main cytokeratin polypeptides expressed were numbers 7, 8, 17, 18 and 19. The tumor-associated antigen CA-125, but not CEA, was shed in the culture supernatant. This was in accordance with FACScan analysis of the cell lines and the level of CA-125 and CEA in the patients' serum. The estrogen and progesterone receptors were negative both in the cell lines and in the original tumors. These new ovarian carcinoma cell lines will be valuable models for further investigations into a variety of biological properties.

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo

“…In some experiments, MDA-MB-435, CAMA-1, MCF-7 breast cancer cells (ATCC), and OV-MZ-6 ovarian cancer cells [19], respectively, were also used. Cells were routinely checked to be free of mycoplasma.…”

Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with Its Receptor (CD87)

“…Briefly, fibrin gels were prepared in 24-well cell culture plates by incubating 200 µl of 50 mg/ml plasminogen-depleted fibrinogen (Calbiochem, Frankfurt, Germany), 50 µl of 150 mM CaCl 2 , and 50 µl of 60 U/ml thrombin (Novagen, Schwalbach, Germany) for 1 h at 37°C. uPA-producing ovarian cancer OV-MZ-6 cells (Möbus et al, 1992;Fischer et al, 1998) were seeded on top of the fibrin gel (4 × 10 4 cells/well) in the presence of plasminogen (2 µg/ml medium) and varying amounts of the respective synthetic uPA-peptides. As controls, the inhibitory monoclonal antibody against human uPA B-chain, mAb # 394 (10 µg/ml), or the amino-terminal fragment of uPA, ATF (2 µg/ml) (both from American Diagnostica, Pfungstadt, Germany) were used.…”

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

“…Twenty-nine human ovarian cancer cell lines were established from primary ovarian cancer tissue as described previously (Mobus et al, 1992). The cells were grown in DulbeccoÕs modified Eagles medium (DMEM) containing 10% fetal calf serum, 200 mM glutamine, and 100 µg ml Ð1 penicillin and 100 µg ml Ð1 streptomycin in 5% carbon dioxide at 37°C and harvested at about 70% confluence.…”